LL, KK & "big pharma". Quick thought on him. There
Post# of 148117
He did not corrupt the data. Was simply pathetic in formatting to FDA regulations. DOD suit says him & the "ceo", were told for 2 years of this, from the FDA. Emails prove it.
So, is it that upon being hired, the data & etc., from the Allen d. Allen time, was a total mess? He saw the weaknesses of that new "ceo". Took payments, continued the formatting shambles. If you're an outside force ( "big pharma" let's say), & you're the ruthless, no morals, profits over all & wanted Leronlimab "dead", then why would you not "kill" it, through your hired traitor, by actually corrupting the data? I think odds are very good when all that settles, outside of us now, ( thank god ) it will be that he was opportunistically lazy. 7 yrs of trials alone, is a head scratcher. So....
Big pharma:
I think saying is a LL threat, is wrong.
It's said of how much they make by not, curing.
Yes, there's alot of treatment drugs administered. But "big pharma", does not own all those ancillary/combo drugs. Pharma could care less what happens to those.
It's said Roche is $220b yearly, as I think ranked #2. So how much larger of a market is lost to what "big pharma", does not control?
Again, it's said they don't want cures, only treatments. But they've never had a therapeutic, for a very, very large # of indications either. With no toxicity, Black Box or drug interactions.
Take AAV as example. They are purifying more & more, to reduce SAE's & side effects. That will combine with sci-fi like movies, in the future. Quick, on the spot administering. They are already planning to build communities on the moon, via 3d printed homes.
The very distant future will require the reduction / death of at least SAE's. Look @ old Schwarzenegger, Tom Cruise, Stallone movies as examples. Science, Ai, tech, & so many other tools, having combined today, will be a huge evolving factor on pharmaceutical future.
Treating vs curing.
How many multiples larger a market do you think treating is, over a cure? The dollar value of the ancillary add-on, supporting of a drug for treatment.
Do you really think "big pharma" will not be willing to find a way to tap into that? How?
By supporting LL, in turn reversing their "business model". Knowing the dollar burden; "fat", LL removes out the system, bp can ( will ) charge more "per shot", per say. Because it would only be a percentage, of the cost burden removed. Yet still far, far more lucrative, because ancillary industry is multiples larger as a whole.
Making even more money, & no longer vilified.
Through Dr. J's press release/webinars, & the Syneos news, we know the FDA is now letting Leronlimab fly.
Leronlimab will eventually, cause a pharmaceutical industry consolidation, unlike anything yet considered.